MRD Assessment in Multiple Myeloma: Progress and Challenges.
Luca BertaminiMattia D'AgostinoFrancesca GayPublished in: Current hematologic malignancy reports (2021)
The achievement of MRD negativity after therapy is considered prognostically important for MM patients, and data from clinical trials and meta-analyses have confirmed that it is strongly associated with better survival. Along with well-known techniques, such as next-generation sequencing (NGS), next-generation flow (NGF), and positron emission tomography/computed tomography (PET/CT), other methods such as mass spectrometry (MS) and circulating tumor cells are under study. Intensive treatment regimens at diagnosis can lead up to 70% of MRD negativity in MM patients, although the current proportion of curable patients is still unknown. Today, clinicians who treat MM deal with MRD assessment in routine clinical practice. Its appropriate use in therapeutic decision making may be the most fascinating and challenging issue to be addressed over the next few years.
Keyphrases
- positron emission tomography
- computed tomography
- end stage renal disease
- pet ct
- mass spectrometry
- newly diagnosed
- ejection fraction
- clinical trial
- chronic kidney disease
- circulating tumor cells
- systematic review
- prognostic factors
- multiple myeloma
- multiple sclerosis
- randomized controlled trial
- machine learning
- gene expression
- artificial intelligence
- copy number
- bone marrow
- pet imaging
- tandem mass spectrometry